欢迎来到天天文库
浏览记录
ID:6070143
大小:29.00 KB
页数:5页
时间:2018-01-02
《厄洛替尼在晚期非小细胞肺癌中临床应用研究》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库。
1、厄洛替尼在晚期非小细胞肺癌中临床应用研究 [摘要]目的探讨厄洛替尼在晚期非小细胞肺癌(NSCLC)患者中的应用价值。方法选择晚期NSCLC(腺癌和鳞癌)患者,腺癌和鳞癌患者均分为未治疗组、化疗组、靶向治疗组及化疗+靶向治疗组。靶向治疗服用厄洛替尼。通过生存分析比较各组中位无进展生存期(PFS)及中位总生存期(OS)。结果肺腺癌及肺非腺癌各自的四组间,中位PFS、OS均存在统计学差异,靶向治疗组中位PFS、OS均较未治疗组的长。肺腺癌患者中,表皮生长因子受体(EGFR)基因突变型组和野生型组的中位OS差别有统计学
2、意义。结论厄洛替尼治疗的晚期NSCLC患者中位PFS及OS较未治疗者长;厄洛替尼治疗的肺腺癌患者,EGFR基因突变型者中位OS较野生型者长。[关键词]厄洛替尼;晚期非小细胞肺癌;生存分析[中图分类号]R734.2[文献标识码]B[文章编号]1673-9701(2013)34-0080-03Analysisonclinicalapplicationoferlotinibinpatientswithadvancednon-smallcelllungcancerCHENWeisongZHUDanCHENHuiLUOJi
3、anfengYANG5XiguangXUJilinWANGLinyingDepartmentofRespiratoryMedicine,JinhuaCentralHospitalinZhejiangProvince,Jinhua321000,China[Abstract]ObjectiveToinvestigatetheapplicationvalueoferlotinibinpatientswithadvancednon-smallcelllungcancer.MethodsPatientswithadvanc
4、edNSCLC(adenocarcinomaandsquamouscellcarcinoma)wereselected,adenocarcinomaandsquamouscellcarcinomapatientswerealldividedintountreatedgroup,chemotherapygroup,targetedtherapygroupandchemotherapycombinatedwithtargetedtherapygroup,targetedtherapygroupweretakenerl
5、otinib.Themedianprogression-freesurvival(PFS)andthemedianoverallsurvival(OS)ofeachgroupwerecomparedbysurvivalanalysis.ResultsAmongtherespectivefourgroupsofadenocarcinomaandsquamouscellcarcinomapatients,theirmedianPFSandmedianOSwereallstatisticallydifferent,th
6、eirtargetedtherapygroupshadlongermedianPFSandmedianOSthantheuntreatedgroups.Amongthepatientswithlungadenocarcinoma,theepidermalgrowthfactor5receptor(EGFR)genemutationsgroupandwild-typegroup’smedianOSdifferencewasstatisticallysignificant.ConclusionAmongthepati
7、entswithadvancedNSCLC,themedianPFSandthemedianOSoferlotinibtreatmentwerelongerthanthatwithnotreatment;Amongthepatientswithlungadenocarcinomatreatedbyerlotinib,patientswithEGFRgenemutationshadlongermedianOSthanthatwithwild-typegene.[Keywords]Erlotinib;Advanced
8、non-smallcelllungcancer;Survivalanalysis肺癌是目前全世界最致命的恶性肿瘤,且发病率和病死率一直呈上升趋势[1]。所有肺癌中非小细胞肺癌(non-smallcelllungcancer,NSCLC)约占85%,且在首次确诊的病例中,有25%~30%为局部晚期,40%~50%已有转移灶[2]。目前含铂类两药联合化疗仍是NSCLC患者的主
此文档下载收益归作者所有